Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Huang, Han Lin ^a   Lee, Hsueh Yun ^b   Tsai, An Chi ^c   Peng, Chieh Yu ^d   Lai, Mei Jung ^b   Wang, Jing Chi ^c   Pan, Shiow Lin ^b,c   Teng, Che Ming ^a   Liou, Jing Ping ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BENZENESULFONYL 2,3 DIHYDRO 1H INDOL 5 YL) N HYDROXY ACRYLAMIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MPT 0E 028; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LINE NCI 60; CELL PROLIFERATION; CELL STRAIN HCT116; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ACETYLATION; ACRYLAMIDE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865171888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043645     Document Type: Article

References (25)

1. Khan O, La Thangue NB, ((2012)) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90:: 85--94.
2. Beumer J, Tawbi H, ((2010)) Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5:: 196--208.
3. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, ((2010)) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3:: 5.
4. Prince HM, Bishton MJ, Harrison SJ, ((2009)) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:: 3958--3969.
5. Marks PA, Xu WS, ((2009)) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:: 600--608.
6. Srivastava RK, Kurzrock R, Shankar S, ((2010)) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9:: 3254--3266.
7. Ellis L, Hammers H, Pili R, ((2009)) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280:: 145--153.
8. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A, ((2008)) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22:: 2159--2168.
9. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, et al. ((2008)) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology 10:: 395--398.
10. Jazirehi AR, ((2010)) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21:: 805--813.
11. Paris M, Porcelloni M, Binaschi M, Fattori D, ((2008)) Histone Deacetylase Inhibitors: From Bench to Clinic. Journal of Medicinal Chemistry 51:: 1505--1529.
12. Venugopal B, Evans T, ((2011)) Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18:: 1658--1671.
13. Chang J-Y, Hsieh H-P, Chang C-Y, Hsu K-S, Chiang Y-F, et al. ((2006)) 7-Aroyl-aminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents. Journal of Medicinal Chemistry 49:: 6656--6659.
14. Chang J-Y, Lai M-J, Chang Y-T, Lee H-Y, Cheng Y-C, et al. ((2010)) Synthesis and biological evaluation of 7-arylindoline-1-benzenesulfonamides as a novel class of potent anticancer agents. MedChemComm 1:: 152.
15. Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, et al. ((2008)) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:: 1054--1065.
16. Paull K, Hamel E, Maalspeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor sreen of the National Cancer Institute, in Cancer Chemotherapeutic Agents. In: Foye W, editor. Cancer chemotherapeutic agents. Washington, DC: American Chemical Society.
17. Khosravi-Far R, White E, Shankar S, Srivastava RK (2007) Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis Programmed Cell Death in Cancer Progression and Therapy. Springer Netherlands. 261-298.
18. Takai N, Narahara H, ((2007)) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14:: 2548--2553.
19. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, et al. ((2007)) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:: 769--774.
20. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, et al. ((2006)) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:: 13548--13558.
21. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, et al. ((2004)) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:: 455--463.
22. Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, et al. ((2010)) Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer 127:: 1384--1392.
23. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, et al. ((2007)) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 39:: 1500--1509.
24. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, et al. ((2005)) RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25:: 8097--8107.
25. Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser K, et al. ((2007)) Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 31:: 1391--1402.